Re: High concordance between immunohistochemistry and fluorescence in situ hybridization testing for HER2 status in breast cancer requires a normalized IHC scoring system.
Hanna
Wedad M
WM
Hammond
Elizabeth
E
Taylor
Clive R
CR
Dabbs
David J
DJ
Penault-Llorca
Frederique
F
Bloom
Kenneth J
KJ
Bilous
Michael
M
Badve
Sunil
S
D014408:Biomarkers, Tumor / Q000235:genetics / Q000378:metabolism; D001943:Breast Neoplasms / Q000175:diagnosis*; D005189:False Positive Reactions; D005260:Female; D006801:Humans; D007150:Immunohistochemistry / Q000379:methods / Q000592:standards; D017404:In Situ Hybridization, Fluorescence / Q000379:methods*; D017410:Practice Guidelines as Topic; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics / Q000378:metabolism; D015203:Reproducibility of Results; D012107:Research Design / Q000592:standards*
D014408:Biomarkers, Tumor; D018719:Erb-b2 Receptor Tyrosine Kinases